{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:03:41Z","timestamp":1783393421640,"version":"3.54.6"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with severe COVID-19 experience cytokine storm, an uncontrolled upregulation of pro-inflammatory cytokines, which if unresolved leads to acute respiratory distress syndrome (ARDS), organ damage, and death. Treatments with mesenchymal stromal cells (MSC) [Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell &amp; Gene Therapy Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21:1019-1024] appear to be effective in reducing morbidity and mortality. MSC respond to pro-inflammatory cytokines by releasing anti-inflammatory factors and mobilizing immune cells. We analyzed 82 COVID-19 clinical trials registered at ClinicalTrials.gov to determine MSC dosing, routes of administration, and outcome measures. Nearly all trials described the use of intravenous delivery with most doses ranging between 50 and 125 million MSC\/treatment, which overlaps with a minimal effective dose range that we described previously. We also searched the literature to analyze clinical trial reports that used MSC to treat COVID-19. MSC were found to improve survival and oxygenation, increase discharge from intensive care units and hospitals, and reduce levels of pro-inflammatory markers. We report on a 91-year-old man with severe COVID-19 who responded rapidly to MSC treatment with transient reductions in several pro-inflammatory markers and delayed improvement in oxygenation. The results suggest that frequent monitoring of pro-inflammatory markers for severe COVID-19 will provide improved treatment guidelines by determining relationships between cytokine storms and ARDS. We propose that markers for cytokine storm are leading indicators for ARDS and that measurement of cytokines will indicate earlier treatment with MSC than is performed now for ARDS in severe COVID-19.<\/jats:p>","DOI":"10.1093\/stcltm\/szac067","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T22:47:59Z","timestamp":1664664479000},"page":"1103-1112","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0447-6634","authenticated-orcid":false,"given":"Martin","family":"Grumet","sequence":"first","affiliation":[{"name":"W. M. Keck Center for Collaborative Neuroscience, Rutgers Stem Cell Research Center, Department of Cell Biology & Neuroscience, Rutgers University , Piscataway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Sherman","sequence":"additional","affiliation":[{"name":"W. M. Keck Center for Collaborative Neuroscience, Rutgers Stem Cell Research Center, Department of Cell Biology & Neuroscience, Rutgers University , Piscataway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry S","family":"Dorf","sequence":"additional","affiliation":[{"name":"W. M. Keck Center for Collaborative Neuroscience, Rutgers Stem Cell Research Center, Department of Cell Biology & Neuroscience, Rutgers University , Piscataway, NJ , USA"},{"name":"Department of Medicine, North Shore University Hospital , Manhasset, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"issue":"9","key":"2022111808294777200_CIT0001","first-page":"e10257","article-title":"Retrospective analysis of inflammatory markers and patient characteristics in hospitalized Covid-19 patients: an early experience in Louisiana","volume":"12","author":"Miatech","year":"2020","journal-title":"Cureus"},{"issue":"7","key":"2022111808294777200_CIT0002","doi-asserted-by":"crossref","first-page":"102569","DOI":"10.1016\/j.autrev.2020.102569","article-title":"Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review","volume":"19","author":"Alijotas-Reig","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2022111808294777200_CIT0003","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/jca.21881","article-title":"Efficacy of convalescent plasma therapy for COVID-19: a systematic review and meta-analysis","volume":"36","author":"Vegivinti","year":"2021","journal-title":"J Clin Apher"},{"issue":"6","key":"2022111808294777200_CIT0004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19\u2014Interim WHO solidarity trial results","volume":"384","author":"Consortium","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"2022111808294777200_CIT0005","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"2022111808294777200_CIT0006","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2022111808294777200_CIT0007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol Biol Rev"},{"issue":"1","key":"2022111808294777200_CIT0008","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jhep.2020.09.031","article-title":"COVID-19: discovery, diagnostics and drug development","volume":"74","author":"Asselah","year":"2021","journal-title":"J Hepatol"},{"key":"2022111808294777200_CIT0009","first-page":"705","article-title":"Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date","volume":"16","author":"Si","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"10","key":"2022111808294777200_CIT0010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","article-title":"Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT(R)) Mesenchymal Stromal Cell committee position statement on nomenclature.","volume":"21","author":"Viswanathan","year":"2019","journal-title":"Cytotherapy"},{"issue":"10","key":"2022111808294777200_CIT0011","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/sctm.20-0186","article-title":"Current status of mesenchymal stem cell therapy for immune\/inflammatory lung disorders: Gleaning insights for possible use in COVID-19","volume":"9","author":"Yen","year":"2020","journal-title":"Stem Cells Transl Med"},{"issue":"5","key":"2022111808294777200_CIT0012","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","article-title":"A phase 3, single-arm, prospective study of Remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2022111808294777200_CIT0013","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/sctm.20-0472","article-title":"Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1\/2a, randomized controlled trial","volume":"10","author":"Lanzoni","year":"2021","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"2022111808294777200_CIT0014","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00134-021-06570-4","article-title":"Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): A multicentre, randomised, double-blind, placebo-controlled phase 1\/2 trial","volume":"48","author":"Bellingan","year":"2022","journal-title":"Intensive Care Med"},{"issue":"1","key":"2022111808294777200_CIT0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/mt.2011.211","article-title":"Mesenchymal stem\/stromal cells (MSCs): role as guardians of inflammation","volume":"20","author":"Prockop","year":"2012","journal-title":"Mol Ther"},{"key":"2022111808294777200_CIT0016","first-page":"19","article-title":"Fate of intravenously injected mesenchymal stem cells and significance for clinical application","volume":"130","author":"Wagner","year":"2013","journal-title":"Adv Biochem Eng Biotechnol"},{"issue":"9","key":"2022111808294777200_CIT0017","doi-asserted-by":"crossref","first-page":"e0207","DOI":"10.1097\/CCE.0000000000000207","article-title":"Placenta-derived cell therapy to treat patients with respiratory failure due to coronavirus disease 2019","volume":"2","author":"Barkama","year":"2020","journal-title":"Crit Care Explor"},{"issue":"12","key":"2022111808294777200_CIT0018","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41422-021-00573-y","article-title":"Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms","volume":"31","author":"Zhu","year":"2021","journal-title":"Cell Res"},{"issue":"1","key":"2022111808294777200_CIT0019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/sctm.19-0202","article-title":"Trends in mesenchymal stem cell clinical trials 2004-2018: is efficacy optimal in a narrow dose range?","volume":"9","author":"Kabat","year":"2020","journal-title":"Stem Cells Transl Med"},{"key":"2022111808294777200_CIT0020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ijid.2020.05.040","article-title":"Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of mesenchymal stromal (stem) cell (MSC) therapy\u2014achieving global consensus and visibility for cellular host-directed therapies","volume":"96","author":"Zumla","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2022111808294777200_CIT0021","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cytogfr.2020.12.002","article-title":"Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy","volume":"58","author":"Barros","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"2022111808294777200_CIT0022","volume-title":"C Reactive Protein.","author":"Nehring","year":"2022"},{"issue":"8","key":"2022111808294777200_CIT0023","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2213-2600(21)00105-3","article-title":"The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?","volume":"9","author":"Matthay","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2022111808294777200_CIT0024","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.chest.2020.09.275","article-title":"Comparative survival analysis of immunomodulatory therapy for coronavirus disease 2019 cytokine storm","volume":"159","author":"Narain","year":"2020","journal-title":"Chest"},{"issue":"5","key":"2022111808294777200_CIT0025","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcyt.2020.11.007","article-title":"Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition","volume":"23","author":"Galipeau","year":"2021","journal-title":"Cytotherapy"},{"key":"2022111808294777200_CIT0026","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.eclinm.2020.100454","article-title":"Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study","volume":"25","author":"Sanchez-Guijo","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2022111808294777200_CIT0027","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/scd.2008.0253","article-title":"Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect","volume":"18","author":"Fischer","year":"2009","journal-title":"Stem Cells Dev"},{"issue":"3","key":"2022111808294777200_CIT0028","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3390\/v13030419","article-title":"Prognostic values of serum ferritin and D-dimer trajectory in patients with COVID-19","volume":"13","author":"Qeadan","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"2022111808294777200_CIT0029","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s13287-020-01875-5","article-title":"Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells","volume":"11","author":"Shu","year":"2020","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"2022111808294777200_CIT0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13287-020-01725-4","article-title":"Intravenous infusion of human umbilical cord Wharton\u2019s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia","volume":"11","author":"Zhang","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"2022111808294777200_CIT0031","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.2147\/IDR.S272645","article-title":"Human umbilical cord mesenchymal stem cells for adjuvant treatment of a critically ill COVID-19 patient: a case report","volume":"13","author":"Zhu","year":"2020","journal-title":"Infect Drug Resist"},{"issue":"5","key":"2022111808294777200_CIT0032","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s11684-020-0810-9","article-title":"Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19","volume":"14","author":"Tang","year":"2020","journal-title":"Front Med"},{"key":"2022111808294777200_CIT0033","first-page":"1","article-title":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial","volume":"5","author":"Meng","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2022111808294777200_CIT0034","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ejvs.2018.11.008","article-title":"PLX-PAD cell treatment of critical limb ischaemia: rationale and design of the PACE trial","volume":"57","author":"Norgren","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"7","key":"2022111808294777200_CIT0035","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1007\/s11010-021-04122-4","article-title":"The most important biomarker associated with coagulation and inflammation among COVID-19 patients","volume":"476","author":"Hong","year":"2021","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"2022111808294777200_CIT0036","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/CRD.0000000000000330","article-title":"Elevated D-dimer levels are associated with increased risk of mortality in Coronavirus disease 2019: a systematic review and meta-analysis","volume":"28","author":"Shah","year":"2020","journal-title":"Cardiol Rev"},{"issue":"5","key":"2022111808294777200_CIT0037","first-page":"333","article-title":"Management of elevated serum ferritin levels","volume":"4","author":"Adams","year":"2008","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"7","key":"2022111808294777200_CIT0038","doi-asserted-by":"crossref","first-page":"102567","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2022111808294777200_CIT0039","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.jaut.2020.102537","article-title":"High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients","volume":"115","author":"Iglesias-Julian","year":"2020","journal-title":"J Autoimmun"},{"issue":"5","key":"2022111808294777200_CIT0040","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s12015-021-10214-x","article-title":"Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey","volume":"17","author":"Ercelen","year":"2021","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"2022111808294777200_CIT0041","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13287-021-02165-4","article-title":"Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series","volume":"12","author":"Hashemian","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"2022111808294777200_CIT0042","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2(\u2212) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis"},{"issue":"22","key":"2022111808294777200_CIT0043","doi-asserted-by":"crossref","first-page":"10554","DOI":"10.1111\/jcmm.16986","article-title":"Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells","volume":"25","author":"Sadeghi","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"1","key":"2022111808294777200_CIT0044","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/stcltm\/szab005","article-title":"Improved MSC minimal criteria to maximize patient safety: a call to embrace tissue factor and hemocompatibility assessment of MSC products","volume":"11","author":"Moll","year":"2022","journal-title":"Stem Cells Transl Med"},{"key":"2022111808294777200_CIT0045","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3389\/fimmu.2020.01091","article-title":"MSC therapies for COVID-19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy","volume":"11","author":"Moll","year":"2020","journal-title":"Front Immunol"},{"key":"2022111808294777200_CIT0046","doi-asserted-by":"crossref","first-page":"789317","DOI":"10.3389\/fimmu.2021.789317","article-title":"Differential co-expression network analysis reveals key hub-high traffic genes as potential therapeutic targets for COVID-19 pandemic","volume":"12","author":"Hasankhani","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"2022111808294777200_CIT0047","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/bit.23233","article-title":"Encapsulated mesenchymal stromal cells for in vivo transplantation","volume":"108","author":"Barminko","year":"2011","journal-title":"Biotechnol Bioeng"},{"issue":"3","key":"2022111808294777200_CIT0048","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nm.4030","article-title":"Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice","volume":"22","author":"Vegas","year":"2016","journal-title":"Nat Med"},{"issue":"8","key":"2022111808294777200_CIT0049","first-page":"647","article-title":"Sizes and sufficient quantities of MSC microspheres for intrathecal injection to modulate inflammation in spinal cord injury","volume":"5","author":"Kumar","year":"2015","journal-title":"Nano Life"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/11\/11\/1103\/47107934\/szac067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/11\/11\/1103\/47107934\/szac067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T08:31:10Z","timestamp":1668760270000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/11\/11\/1103\/6743286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,1]]},"published-print":{"date-parts":[[2022,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szac067","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,10,1]]}}}